Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used in this study, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy on March 27, 2017.

The homologous recombination related gene mutations in total endometrial cancer accounted for 22%. Homologous Recombination Repair Defect (HRD) +ARID1A accounted for 48%, and 53% of endometrial cancer cell lines were sensitive to PARP inhibitors. The incidence of HRD in endometrial cancer with high copy number (the pathological type is mainly ESC) is 50%, suggesting potential clinical applications of PARP inhibitors for the treatment of ESC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

NCT04080284

Endometrial Cancer Papillary Serous Endometrial Carcinoma Uterine Serous Carcinoma +2 more

COMPLETED PHASE2

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

NCT04395612

Cervical Cancer

UNKNOWN PHASE2

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05162872

Nasopharyngeal Carcinoma

UNKNOWN PHASE2

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

NCT04641247

Ovarian Neoplasms Breast Neoplasms

RECRUITING PHASE2

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

NCT06771596

Uterine Cervical Neoplasms

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Carcinoma Serous Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Niraparib as maintenance therapy for Endometrial Serous Carcinoma

For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.

Group Type EXPERIMENTAL

Niraparib

Intervention Type DRUG

Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.

Niraparib as recurrent therapy for Endometrial Carcinoma

For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.

Group Type EXPERIMENTAL

Niraparib

Intervention Type DRUG

Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Niraparib

Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 18 or above
* Histological confirmation of serous endometrial cancer or other types of endometrial cancer
* FIGO stage III-IV
* ESC Patients have received at least 6 cycles of first-line platinum containing chemotherapy after surgery and achieved CR, PR or SD; ESC patients have received platinum containing chemotherapy after the first relapse and achieved CR, PR or SD; these two types of patients are enrolled in cohort 1 and receive niraparib alone as maintenance therapy within 12 weeks after the last chemotherapy treatment.
* ESC Patients have received \>2 lines of platinum containing chemotherapy and relapsed; patients with other types of endometrial cancer have received \>2 lines of platinum containing chemotherapy and have BRCA mutation or be defined as HRD positive; these 2 types of patients are enrolled in cohort 2 and receive niraparib monotherapy.
* Radiotherapy or endocrine therapy history is allowed
* Cohort 1 life expectancy\> 6 months; Cohort 2 life expectancy\> 4 months
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Patients agreed to provide blood samples for testing BRCA status and HRR mutations.
* Patients agreed to provide formalin-fixed and paraffin-embedded tumor tissue samples for the detection of homologous recombination repair related genes (optional)
* Laboratory criteria are as follows:
* Neutrophil count ≥1500/µL;Platelets ≥100,000/µL;Hemoglobin ≥10g/dL;Serum creatinine ≤1.5 times of the upper limit, or creatinine clearance ≥60mL/min;Total bilirubin ≤1.5 times of the upper limit or direct bilirubin ≤1.0 times of the upper limit;AST and ALT ≤2.5 times of the upper limit, and must be ≤5 times of the upper limit of when liver metastasis exists.
* Patients of reproductive potential must have a negative urinary or serum pregnancy test when done and promise to take effective contraceptive measuresduring the period of the study; Or without potential fertility, defined as:
* Women who have undergone contraceptive operation(hysterectomy, bilateral oophorectomy or bilateral salpingectomy), or
* over 60 years old, or≥40 and \<60 years of age, menopause for more than 12 months, and follicle-stimulating hormone test results are within the reference range of research institutions after menopause
* Willingness to sign a written informed consent document and follow the plan
* Any previous toxic and side effects of chemotherapy have recovered to ≤ CTCAE level 1 or baseline level, except for sensory neuropathy or hair loss with stable symptoms ≤ CTCAE level 2

Exclusion Criteria

* Allergic to active or inactive ingredients of ZL-2306 (nirapali) or drugs with similar chemical structure to ZL-2306 (nirapali)
* Stage Ia(on invasion to myometrium)
* Symptomatic, uncontrollable brain metastases or pial metastases(No imaging scan is required); patients with spinal cord compression can still be considered for enrollment if they have received targeted therapy and have evidence of clinically SD for at least 28 days (patients with controlled central nervous system metastasis must have received radiotherapy or chemotherapy at least 1 month before and with no new symptoms related to central nervous system lesions or symptoms suggesting disease progression)
* Received surgery within 3 weeks before the start of the study, or any surgical effects that have not recovered.
* Received palliative radiotherapy with \>20% bone marrow 1 week before enrollment
* Suffered from other aggressive cancers (except for fully treated basal or squamous cell skin cancer) within 2 years before enrollment
* Previously or currently diagnosed as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
* Suffer from serious or uncontrollable diseases, including but not limited to:
* Uncontrollable nausea and vomiting, inability to swallow drugs, any gastrointestinal diseases that may interfere with drug absorption and metabolism
* Active viral infections such as human immunodeficiency virus, hepatitis B, hepatitis C, etc.
* Uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other mental disorders
* Immune deficiency (except for splenectomy)
* Any past or current disease, treatment or laboratory abnormality that may interfere with the results of the study, or be defined as not suitable for this study
* Receive platelet or red blood cell transfusion within 4 weeks before the start of the study.
* Pregnant or breastfeeding, or expect to become pregnant during the study.
* Have received any PARP inhibitor treatment previously.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No